Targeting mTOR with MLN0128 Overcomes Rapamycin and Chemoresistant Primary Effusion Lymphoma
ABSTRACT Primary effusion lymphoma (PEL) is caused by Kaposi’s sarcoma-associated herpesvirus (KSHV). PEL has a highly active mTOR pathway, which makes mTOR a potential therapeutic target. MLN0128 is an ATP-competitive inhibitor of mTOR that has entered clinical trials for solid tumors. Our results...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | article |
| Language: | EN |
| Published: |
American Society for Microbiology
2019
|
| Subjects: | |
| Online Access: | https://doaj.org/article/9e5c6d0be51c4fd4bea1e3aa9ddf3942 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|